People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Brenig Therapeutics, Inc. | — | Biotechnology | Series B | $30.0M | $210.0M | 2024 |
| ApoGen Biotechnologies, Inc. | — | Biotechnology | Series A | $7.6M | $273.5M | 2016 |
Keno Gutierrez at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Keno Gutierrez on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Asish Xavier | 1 | 18 |
| Steve Gillis | 1 | 13 |
| Edward Mathers | 1 | 12 |
| Thong Le | 1 | 12 |
| Joel Marcus | 1 | 9 |
| James Sullivan | 1 | 7 |
| Lindsay Rayle | 1 | 7 |
| David Schubert | 1 | 6 |
| Iain Dukes | 1 | 5 |
| Joel Johnston Marcus | 1 | 5 |
| M. Johnston Erwin | 1 | 5 |
| John Santini | 1 | 5 |
| Nikolay Savchuk | 1 | 3 |
| James Johnston Sullivan | 1 | 3 |
| Ian A.W. Howes | 1 | 2 |
| David McElligott | 1 | 2 |
| Michele Cucullu | 1 | 1 |
| John Johnston Santini | 1 | 1 |
| Johnston Erwin | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.